After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, RNA falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Avidity Biosciences Inc is $3.61B. A total of 1.02 million shares were traded on the day, compared to an average of 1.36M shares.
In the most recent transaction, Gallagher Kathleen P. sold 5,875 shares of RNA for 29.41 per share on Mar 03 ’25. After the transaction, the Chief Program Officer now owns 50,554 company shares. In a previous transaction on Feb 03 ’25, Gallagher Kathleen P. sold 5,875 shares at 32.16 per share. RNA shares that Chief Program Officer owns now total 50,554.
Among the insiders who bought shares, KATHLEEN GALLAGHER acquired of 17,625 shares on Feb 03 ’25 at a per-share price of $32.93. In another insider transaction, LEVIN ARTHUR A sold 1,872 shares at $28.60 per share on Jan 21 ’25. Company shares held by the Director now total 12,958.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RNA has a high of $56.00 and a low of $20.34.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $11.89, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.82.
